AR and prostate carcinoma: Studies on the influence of MCP inhibitors and the role of glutamine metabolism in cell proliferation and metabolism of prostate cancer cells suggest that there are fundamental differences in the metabolic characteristics of AR-positive and AR-negative prostate cancer [42,47].